Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2004 | |
| Cash Flows From Operating Activities | |
| Net Income | -9,474 |
| Depreciation Amortization | 377 |
| Accounts receivable | 29 |
| Accounts payable and accrued liabilities | 416 |
| Other Working Capital | 417 |
| Other Operating Activity | -378 |
| Operating Cash Flow | $-8,615 |
| Cash Flows From Investing Activities | |
| PPE Investments | -415 |
| Investing Cash Flow | $-415 |
| Cash Flows From Financing Activities | |
| Debt Repayment | -43 |
| Other Financing Activity | 18,189 |
| Financing Cash Flow | $18,146 |
| Exchange Rate Effect | -22 |
| Beginning Cash Position | 7,166 |
| End Cash Position | 16,260 |
| Net Cash Flow | $9,094 |
| Free Cash Flow | |
| Operating Cash Flow | -8,615 |
| Capital Expenditure | -415 |
| Free Cash Flow | -9,029 |